Zynex to Present at the SeeThruEquity Disruptive Growth Company Showcase PR Newswire LONE TREE, Colo., Sept. 21, 2017 LONE TREE, Colo., Sept. 21, 2017 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that Thomas Sandgaard, Founder and CEO, will present at the SeeThruEquity Disruptive Growth Company Showcase on Wednesday September 27, 2017 at 11:30 am EDT. The conference will be held at the Grand Hyatt in New York City. Management will also be meeting with members of the investment community during one-on-one meetings. Zynex A live audio webcast and copy of the presentation can be accessed through the "Investors" section of the Company's website at www.zynex.com. Interested parties unable to listen to the live webcast can access an archived version on the Company's website for approximately 90 days. About Zynex Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com. Safe Harbor Statement Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our international expansion efforts, our ability to engage additional sales representatives and their success, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation, our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website. Contact: Zynex, Inc. (303) 703-4906 Investor Relations Contact: Amato And Partners, LLC Investor Relations Counsel email@example.com View original content with multimedia:http://www.prnewswire.com/news-releases/zynex-to-present-at-the-seethruequity-disruptive-growth-company-showcase-300523383.html SOURCE Zynex Website: http://www.zynexmed.com
Zynex to Present at the SeeThruEquity Disruptive Growth Company Showcase
Press spacebar to pause and continue. Press esc to stop.